AP660A - A method of treatment of parasitic infection using IgE antagonists. - Google Patents

A method of treatment of parasitic infection using IgE antagonists. Download PDF

Info

Publication number
AP660A
AP660A APAP/P/1996/000875A AP9600875A AP660A AP 660 A AP660 A AP 660A AP 9600875 A AP9600875 A AP 9600875A AP 660 A AP660 A AP 660A
Authority
AP
ARIPO
Prior art keywords
ige
antibody
antagonist
receptor
parasite
Prior art date
Application number
APAP/P/1996/000875A
Other languages
English (en)
Other versions
AP9600875A0 (en
Inventor
Payman Amiri
Mary Haak-Frendscho
Paula M Jardieu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AP9600875A0 publication Critical patent/AP9600875A0/xx
Application granted granted Critical
Publication of AP660A publication Critical patent/AP660A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/1996/000875A 1994-01-18 1995-01-05 A method of treatment of parasitic infection using IgE antagonists. AP660A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18408394A 1994-01-18 1994-01-18
PCT/US1995/000087 WO1995019181A1 (en) 1994-01-18 1995-01-05 A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS

Publications (2)

Publication Number Publication Date
AP9600875A0 AP9600875A0 (en) 1997-01-31
AP660A true AP660A (en) 1998-08-18

Family

ID=22675480

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000875A AP660A (en) 1994-01-18 1995-01-05 A method of treatment of parasitic infection using IgE antagonists.

Country Status (10)

Country Link
US (1) US5656273A (de)
EP (1) EP0739214B1 (de)
JP (1) JP3825798B2 (de)
AP (1) AP660A (de)
AT (1) ATE164079T1 (de)
DE (1) DE69501817T2 (de)
DK (1) DK0739214T3 (de)
MX (1) MX9602818A (de)
PH (1) PH31447A (de)
WO (1) WO1995019181A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137649A (en) * 1998-02-18 2004-08-31 Genentech Inc Method of adsorption chromatography
WO2000015260A1 (en) * 1998-09-16 2000-03-23 Tanox, Inc. Anti-ige gene therapy
AU766492B2 (en) * 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
US20050031609A1 (en) * 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
WO2002094228A1 (en) * 2001-05-23 2002-11-28 David Follansbee Prevention and treatment of allergies by helminthic regulation of ige
CA2473144C (en) 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP2284192A3 (de) * 2002-11-08 2011-07-20 Ablynx N.V. Antikörper aus Camelidae zur sublingualen Verabreichung
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
HUE029951T2 (en) 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
US20050065136A1 (en) * 2003-08-13 2005-03-24 Roby Russell R. Methods and compositions for the treatment of infertility using dilute hormone solutions
WO2005105106A2 (en) * 2004-04-21 2005-11-10 Roby Russell R Hormone treatment of macular degeneration
US20060025390A1 (en) * 2004-07-28 2006-02-02 Roby Russell R Treatment of hormone allergy and related symptoms and disorders
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
PL2061444T3 (pl) * 2006-09-11 2011-09-30 Bausch & Lomb Kompozycje i sposoby leczenia, traktowania, kontrolowania, redukowania, łagodzenia lub zapobiegania alergii
US20110105559A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and Methods for Treating, Controlling, Reducing, Ameliorating, or Preventing Allergy
US20110104159A1 (en) * 2006-09-11 2011-05-05 Rohrs Brian R Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079280A1 (en) 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
CN105315323A (zh) 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
US20100190963A1 (en) 2008-12-16 2010-07-29 Millipore Corporation Stirred Tank Reactor And Method
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
EP3736338A1 (de) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Verbesserte proteinreinigung durch eine modifizierte protein-a-elution
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
CN102958538A (zh) 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法
EP2571903B1 (de) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulusreaktive polymere zur aufreinigung von biomolekülen
WO2011150241A2 (en) 2010-05-28 2011-12-01 Genentech, Inc. Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
ES2809211T3 (es) 2011-07-08 2021-03-03 Emd Millipore Corp Filtros de profundidad mejorados para procesos biotecnológicos desechables
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
RU2017139267A (ru) 2012-03-27 2019-02-12 Дженентек, Инк. Усовершенствованные способы выделения рекомбинантных белков
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP2934602B1 (de) 2012-12-19 2019-02-27 Genentech, Inc. Verfahren und zusammensetzungen zur radiohalogen proteinmarkierung
WO2016007752A1 (en) 2014-07-09 2016-01-14 Genentech, Inc. Ph adjustment to improve thaw recovery of cell banks
CN109312299A (zh) 2016-03-29 2019-02-05 格尔托公司 蛋白质在具有0.5:1至10:1的周质体积与细胞质体积比的革兰氏阴性菌中的表达
KR102579836B1 (ko) 2016-12-22 2023-09-15 제넨테크, 인크. 동결건조된 폴리펩타이드의 재구성 시간을 감소시키기 위한 방법 및 제제
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
RS65472B1 (sr) 2018-07-03 2024-05-31 Bristol Myers Squibb Co Postupak proizvodnje rekombinantnih proteina
US12415980B2 (en) 2018-10-10 2025-09-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
TW202104254A (zh) 2019-04-12 2021-02-01 美商格爾托公司 重組彈性蛋白及其生產
EP4007808A1 (de) 2019-08-01 2022-06-08 Bristol-Myers Squibb Company Verfahren zur verbesserung der proteinproduktivität in fed-batch-zellkulturen
US12486525B2 (en) 2020-09-22 2025-12-02 Bristol-Myers Squibb Company Methods for increasing productivity of therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0476226A1 (de) * 1990-09-18 1992-03-25 Shionogi Seiyaku Kabushiki Kaisha Monoklonale Antikörper gegen menschliches IgE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946788A (en) * 1985-06-11 1990-08-07 Ciba-Geigy Corporation Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications
US4714759A (en) * 1985-12-02 1987-12-22 Whitaker Jr Robert B Immunotoxin therapy of allergy
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
US5252467A (en) * 1987-12-31 1993-10-12 Tanox Biosystems, Inc. Method of making antibodies to antigenic epitopes of IGE present on B cells but not basophil cell surface or secreted, soluble IGE
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DE122006000007I2 (de) * 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.
DK0602126T3 (da) * 1991-08-14 2003-06-16 Genentech Inc Immunoglobulinvarianter til specifikke FC epsilon-receptorer
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0476226A1 (de) * 1990-09-18 1992-03-25 Shionogi Seiyaku Kabushiki Kaisha Monoklonale Antikörper gegen menschliches IgE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 92,no. 3, September 1993 ST.LOUIS, MO, USA, pages 404-411 *

Also Published As

Publication number Publication date
DK0739214T3 (da) 1998-10-07
JPH10503749A (ja) 1998-04-07
WO1995019181A1 (en) 1995-07-20
EP0739214A1 (de) 1996-10-30
DE69501817D1 (de) 1998-04-23
PH31447A (en) 1998-11-03
ATE164079T1 (de) 1998-04-15
MX9602818A (es) 1997-06-28
AP9600875A0 (en) 1997-01-31
US5656273A (en) 1997-08-12
EP0739214B1 (de) 1998-03-18
JP3825798B2 (ja) 2006-09-27
DE69501817T2 (de) 1998-09-10

Similar Documents

Publication Publication Date Title
US5656273A (en) Method of treatment of parasitic infection using IgE antagonists
EP0841946B1 (de) Verfahren zur behandlung von allergischem asthma
US6660266B1 (en) Reversal of proinflammatory response by ligating the macrophage FcγRI receptor
KR100493980B1 (ko) 면역학적질병의치료를위한치료제로서가용성림포톡신-베타수용체및항-림포톡신수용체및리간드항체
MXPA98000760A (en) Methods for the treatment of asthma allergy
US20110311520A1 (en) Methods for treatment of allergic asthma
JPH08505365A (ja) 自己免疫疾患および炎症性疾患の治療
EP1159003B1 (de) Antikörper gegen tnf alpha zur therapie von steroidresistentem asthma
US20090010928A1 (en) Anti-anthrax antibody, formulations thereof, and methods of use
US9587034B2 (en) Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
US20020076404A1 (en) Treating atopic dermatitis with IgE antagonists
WO1997010004A1 (en) Methods for treatment of interstitial cystitis
WO1999038531A1 (en) TREATING ATOPIC DERMATITIS WITH IgE ANTAGONISTS
US20020006402A1 (en) Administering IgE antagonists during pregnancy to ameliorate allergic diseases in the offspring
Salagean et al. IgE and Anti-IgE Therapy in Allergic Asthma and Rhinitis
WO1998046255A1 (en) Inhibition of b-1 cell mediated immune conditions